Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Jie J. Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5447-893X; OpenAlex author ID A5080372466. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 14)
Trials
0
Grants
0
Labs led
2
Collaborators
47
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 4 papers · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 25

  1. Retraction Note: hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Co-author DOI 10.1038/s41416-025-03268-y↗
  2. Targeting protein modification: a new direction for immunotherapy of pancreatic cancer. Last author DOI 10.7150/ijbs.101861↗
  3. Progress of single-cell RNA sequencing combined with spatial transcriptomics in tumour microenvironment and treatment of pancreatic cancer. Last author DOI 10.1186/s12967-024-05307-3↗
  4. Plasma metabolites as mediators in immune cell-pancreatic cancer risk: insights from Mendelian randomization. Last author DOI 10.3389/fimmu.2024.1402113↗
  5. Advancement of single-cell sequencing for clinical diagnosis and treatment of pancreatic cancer. Last author DOI 10.3389/fmed.2023.1213136↗
  6. The long non-coding RNA EGOT promotes pancreatic cancer progression by sequestering miR-214 to derepress PLS3 expression Co-author DOI 10.21203/rs.3.rs-1415870/v1↗
  7. RAB10 involves in glucose uptake in pancreatic cancer cells by regulating GLUT1 expression and translocating GLUT1 to the cell membrane, which predicts poor pr… Last author DOI 10.21203/rs.3.rs-1618062/v1↗
  8. RAB10 involving in glucose uptake by regulating GLUT1 predicts poor prognosis in pancreatic cancer Last author DOI 10.21203/rs.3.rs-1671317/v1↗
  9. FAM81A identified as a stemness-related gene by screening DNA methylation sites based on machine learning-accessed stemness in pancreatic cancer. Co-author DOI 10.2217/epi-2022-0098↗
  10. Overexpressed CA12 has prognostic value in pancreatic cancer and promotes tumor cell apoptosis via NF-κB signaling. Last author DOI 10.1007/s00432-020-03447-9↗
  11. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000024651↗
  12. Discovery and Validation of Circulating EVL mRNA as a Prognostic Biomarker in Pancreatic Cancer. Last author DOI 10.1155/2021/6656337↗
  13. Expression and prognostic analyses of SCAMPs in pancreatic adenocarcinoma. Last author DOI 10.18632/aging.202377↗
  14. PLS3 predicts poor prognosis in pancreatic cancer and promotes cancer cell proliferation via PI3K/AKT signaling. Last author DOI 10.1002/jcp.29685↗
  15. High Expression of COL17A1 Predicts Poor Prognosis and Promotes the Tumor Progression via NF-κB Pathway in Pancreatic Adenocarcinoma. Last author DOI 10.1155/2020/8868245↗
  16. Identification of lncRNAs and Their Functional Network Associated with Chemoresistance in SW1990/GZ Pancreatic Cancer Cells by RNA Sequencing. Last author DOI 10.1089/dna.2018.4312↗
  17. The involvement of lncRNAs in the development and progression of pancreatic cancer. Last author DOI 10.1080/15384047.2017.1385682↗
  18. LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer. First author DOI 10.18632/oncotarget.16462↗
  19. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. Co-author DOI 10.1093/abbs/gmv129↗
  20. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine. First author DOI 10.18632/oncotarget.7447↗
  21. Marital status independently predicts pancreatic cancer survival in patients treated with surgical resection: an analysis of the SEER database. Last author DOI 10.18632/oncotarget.8467↗
  22. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Co-author DOI 10.1016/j.canlet.2012.11.005↗
  23. Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines. Co-author DOI 10.1016/s1499-3872(11)60014-3↗
  24. Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an i… Co-author DOI 10.1097/mpa.0b013e318217945e↗
  25. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Co-author DOI 10.4414/smw.2011.13208↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xinyu Ge · 6 shared papers, 2022–2025 · strength 1.28
  2. Peng Xu · 10 shared papers, 2016–2021 · strength 1.12
  3. Jianjun Qian · 9 shared papers, 2016–2022 · strength 1.07
  4. Zhennan Li · 10 shared papers, 2016–2022 · strength 1.06
  5. Jie Zhu · 4 shared papers, 2023–2025 · strength 0.92
  6. Zechang Xin · 6 shared papers, 2020–2022 · strength 0.82
  7. Yan Du · 5 shared papers, 2020–2021 · strength 0.66
  8. Feiyu Mao · 5 shared papers, 2020–2021 · strength 0.66
  9. Lijie Cai · 3 shared papers, 2022 · strength 0.52
  10. Ke Zhang · 2 shared papers, 2023–2025 · strength 0.47
  11. Duguang Li · 4 shared papers, 2017–2020 · strength 0.39
  12. Xiaofeng Xue · 3 shared papers, 2011–2025 · strength 0.29
  13. Fei Wang · 1 shared paper, 2025 · strength 0.24
  14. Miao Yi · 1 shared paper, 2025 · strength 0.24
  15. Jia Wei · 1 shared paper, 2025 · strength 0.24
  16. Ke Zhang · 1 shared paper, 2024 · strength 0.20
  17. Qiang Zhang · 1 shared paper, 2022 · strength 0.17
  18. Peng Liu · 1 shared paper, 2022 · strength 0.16
  19. Aman Xu · 1 shared paper, 2021 · strength 0.16
  20. Peng Liu · 1 shared paper, 2022 · strength 0.16
  21. Qingbo Feng · 1 shared paper, 2021 · strength 0.15
  22. Yong An · 3 shared papers, 2011–2017 · strength 0.12
  23. Huihua Cai · 2 shared papers, 2011–2017 · strength 0.09
  24. Wentao Gao · 3 shared papers, 2011–2013 · strength 0.08
  25. Yi Miao · 3 shared papers, 2011 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.